Markets

Actavis and Rhythm Start Mid-Stage Study on Relamorelin - Analyst Blog

A generic image of a calculator, a person holding a pen and papers laid out on a table.
Credit: Shutterstock photo

ActavisACT and biopharmaceutical company, Rhythm, announced the initiation of a phase IIb study on relamorelin. The study is assessing the efficacy and safety of relamorelin (10 mcg to 100 mcg) over three months for the treatment of gastroparesis in patients suffering from type I and II diabetes.

We note that Actavis has an exclusive option to acquire Rhythm Pharmaceuticals, a wholly owned subsidiary of Rhythm, on completing the phase IIb study.

Actavis had entered into an agreement with Rhythm in Oct 2014. As per the terms of the agreement Actavis gained the acquisition option along with the worldwide rights to relamorelin for an undisclosed amount.

Rhythm has already completed two phase II studies on relamorelin. In the first phase II study, patients suffering from diabetic gastroparesis and treated with relamorelin (10 mcg twice daily) showed statistically significant improvements in gastric emptying and vomiting symptoms. Also, results showed statistically significant improvements in other gastroparesis symptoms in a pre-specified subgroup.

In the other study, a phase IIa on relamorelin in chronic constipation patients, those treated with the candidate showed statistically significant improvements in spontaneous bowel movements and in lower gastrointestinal transit. Relamorelin was generally well tolerated in both the studies.

Relamorelin enjoys a Fast Track review status in the U.S. for the treatment of diabetic gastroparesis.

Ironwood Pharmaceuticals IRWD is also developing a candidate (IW-9179) for diabetic gastroparesis. The candidate is in a phase IIa study with data expected in the first half of 2016.

Actavis currently carries a Zacks Rank #2 (Buy). Some other favorably ranked stocks in the health care sector include Akorn, Inc. AKRX and Mallinckrodt MNK . Both hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

IRONWOOD PHARMA (IRWD): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

AKORN INC (AKRX): Get Free Report

ACTAVIS PLC (ACT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MNK IRWD ACT

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More